Clinical trials
Metastatic Cancer clinical trials
Below are recruiting metastatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,881 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05668650RecruitingPhase 3
Study MB12 versus Keytruda for newly diagnosed stage IV lung cancer
This Phase 3 trial compares MB12 with Keytruda (both cancer medicines) for people with newly diagnosed stage IV non-squamous non-small-cell lung cancer. It looks at whether MB12 can work as well or better than Keytruda, and compares safety and immune responses.
Viedma, Río Negro ProvinceAges 18 years+ - NCT06517953RecruitingPhase 2
Testing two targeted pills for rare EGFR lung cancer
This study tests two oral targeted drugs, Befotertinib and Icotinib, in people with advanced lung cancer (NSCLC) that has one of three uncommon EGFR mutations. The trial aims to see how well these pills work when used as the first treatment for your cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06667960RecruitingPhase 1/Phase 2
Study of JK06 for advanced solid tumors
This trial tests a new drug called JK06 for people with advanced solid tumors that cannot be removed by surgery or have spread. It aims to see if JK06 is safe and effective.
AntwerpAges 18 years+ - NCT05727163RecruitingPhase 2
Liver-directed chemotherapy versus standard chemotherapy for RAS-mutated CRC
This Phase 2 study tests whether delivering chemotherapy directly into the liver (with an IV medicine added, depending on the group) works better than standard chemotherapy given through a vein. It is for people whose colorectal cancer has spread to the liver but can’t be removed by surgery yet.
Guangzhou, GuangdongAges 18–75 - NCT07012954RecruitingPhase 1/Phase 2
ctDNA-guided treatment for RAS/BRAF wild-type colorectal cancer
This trial tests a combination of two drugs—cetuximab or bevacizumab plus a chemotherapy pill (trifluridine/tipiracil)—for people with metastatic colorectal cancer that has no RAS or BRAF mutations. It's for patients whose cancer grew after first responding to cetuximab, and who have had other treatments since then.
Guangzhou, GuangdongAges 18–75 - NCT07193862RecruitingEarly Phase 1
Testing a tiny device to find best treatments for liver tumors
This study tests a tiny device that is placed in your liver tumor during surgery. It checks how well different chemotherapy drugs work on your specific cancer, which may help your doctor choose the best treatment for you.
Lake Success, New YorkAges 18 years+ - NCT06106802RecruitingPhase 2
Testing lazertinib and tepotinib for EGFR lung cancer that progressed on lazertinib
This trial tests a combination of two targeted drugs, lazertinib and tepotinib, for people with advanced EGFR-mutant non-small cell lung cancer whose tumors show MET overactivity (high MET levels or MET gene copies) and have grown despite prior treatment with lazertinib. It aims to see if adding tepotinib can overcome that resistance.
Seoul, Gangnam-guAges 19 years+ - NCT07172282RecruitingEarly Phase 1
Immunotherapy for colorectal cancer liver metastases
This trial tests a new way to deliver immunotherapy directly into the liver for people with colorectal cancer that has spread only to the liver. The goal is to see if this approach can shrink tumors before surgery, and it may be an option if you've already had standard chemotherapy.
Lake Success, New YorkAges 18 years+ - NCT07192900RecruitingPhase 1
Fast TILs for metastatic cancer with pleural disease
This trial tests a new therapy using your own immune cells (called TILs) to treat cancer that has spread to the lining of the lungs. The goal is to see if these cells can shrink tumors and help you feel better.
Pittsburgh, PennsylvaniaAges 18–79 - NCT05245136Recruiting
Blood test study for advanced cancer monitoring
This study uses a blood test (liquid biopsy) to look for tumor DNA in patients with advanced cancer. It aims to see if this test can help doctors monitor the cancer and make better treatment decisions.
Augsburg, BavariaAges 18 years+ - NCT07524140RecruitingPhase 1
Study of ZE94-0605 for advanced solid tumors
This trial tests a new drug called ZE94-0605 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and can shrink tumors.
Kogarah, New South WalesAges 18 years+ - NCT05799144RecruitingPhase 2
Pembrolizumab plus investigational HPV drugs for throat cancer
This Phase 2 trial studies pembrolizumab (an immune therapy) combined with investigational treatment(s) pBI-11 and TA-HPV for advanced or recurrent oropharyngeal cancer that is HPV-positive and has certain immune marker levels (PD-L1 CPS ≥ 1). It may help your immune system better attack cancer.
Birmingham, AlabamaAges 18 years+ - NCT03658785RecruitingPhase 1/Phase 2
Immunotherapy for advanced solid tumors using patient tumor cells
This trial tests an immunotherapy made from your own tumor-fighting immune cells (TIL). It may help people with advanced solid cancers that cannot be cured with surgery or radiation.
Wuhan, HubeiAges 18–70 - NCT07028125RecruitingPhase 4
Digital symptom tracking for kidney cancer treatment
This trial tests whether tracking your symptoms with a digital app can help manage side effects while you receive two medications (cabozantinib and nivolumab) for advanced clear-cell kidney cancer that hasn't been treated before.
AnnecyAges 18 years+ - NCT04534543Recruiting
Imaging scans to personalize chemotherapy for liver spread of bowel cancer
This trial tests whether special liver imaging can help doctors choose or guide the best chemotherapy for people with liver metastases from gastrointestinal cancer. The study focuses on comparing imaging-based information with outcomes during common chemo treatments like CAPOX or FOLFOX.
AmsterdamAges 18 years+ - NCT04621435RecruitingPhase 1
PET imaging test for solid tumors using FAP-2286
This Phase 1 study tests a special imaging scan (using FAP-2286) to see solid tumors in people who have already been diagnosed. It may help doctors better detect where cancer is in the body and how to plan treatment.
San Francisco, CaliforniaAges 18 years+ - NCT04842266Recruiting
Light treatment to stabilize pelvic fractures and reduce pain
This trial studies a device called IlluminOss that uses light to help stabilize pelvic fractures and treat pain. It is for people whose pelvic fracture is caused by cancer-related bone damage or frailty, and who already have the IlluminOss pelvic implant planned as part of standard care.
Boston, MassachusettsAges 21 years+ - NCT05339568Recruiting
Smartphone support program for people with advanced lung cancer
This trial tests a “whole process follow-up” care plan, using a smartphone, to support people with non-small cell lung cancer from diagnosis through treatment and follow-up. It may help you manage care steps more smoothly if you’re not a candidate for curative (radical) treatment or don’t want surgery.
Jinan, ShandongAges 18 years+ - NCT04983199Recruiting
Tablet and app program during palliative radiation for cancer pain
This study checks whether a mobile app and wearable sensor can help collect patient-reported outcomes during palliative radiation for cancer pain. It may help researchers better understand symptoms and pain control from the patient’s perspective.
Toronto, OntarioAges 18 years+ - NCT05047094Recruiting
DaRT radiation plus pembrolizumab for head and neck cancer
This trial tests whether a targeted internal radiation treatment (DaRT) combined with pembrolizumab (an immune therapy) can shrink recurrent or metastatic head and neck squamous cell cancer that cannot be fully removed with surgery. It may help by making cancer more visible to the immune system while delivering localized radiation to a tumor area.
JerusalemAges 18 years+ - NCT05100342Recruiting
Testing a points score to predict 30-day survival
This study checks whether a prediction “points score” can estimate the chance of being alive 30 days after a person is referred for comfort-focused radiation therapy. It may help doctors choose the most helpful next steps and better plan follow-up care.
Avon, IndianaAges 18 years+ - NCT05208047RecruitingPhase 3
CGT9486 plus sunitinib for advanced gastrointestinal stromal tumors
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
Birmingham, AlabamaAges 18 years+ - NCT05260671RecruitingPhase 2
Penpulimab plus cetuximab for advanced head and neck cancer
This trial studies penpulimab (an immune medicine) combined with cetuximab (an antibody drug) for recurrent or metastatic squamous cell head and neck cancer that cannot be treated with surgery or radiation. It aims to shrink tumors and improve survival in people whose tumor shows a specific immune marker (PD-L1).
Changchun, JilinAges 18–80 - NCT05495295RecruitingPhase 1
First test of PhOx430 for advanced solid tumors
This Phase 1 trial tests a new cancer drug, PhOx430, for people with advanced (metastatic) solid tumors that have not responded to standard treatments. It aims to find a safe dose and to see whether the drug can shrink or control cancer.
MontpellierAges 18–80
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic cancer?
- Yes. Clin2 currently lists 1,881 recruiting metastatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.